Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Chembiochem : a European Journal of Chemical Biology
|
January 7, 2012
A new concept for glycosyltransferase inhibitors: nonionic mimics of the nucleotide donor of the human blood group B galactosyltransferase
Katrin Schaefer, Joachim Albers, Nora Sindhuwinata, et al.
Cancers
|
January 11, 2024
DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models
Steffie Revia, Magdalena A Budzinska, Olga Bogatyrova, et al.
Plos One
|
October 6, 2017
Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma
Laura P Brandt, Joachim Albers, Tomas Hejhal, et al.
International Journal of Molecular Sciences
|
May 25, 2024
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models
Steffie Revia, Felix Neumann, Julia Jabs, et al.
Bone
|
October 3, 2009
Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism
Jochen Schulze, Joachim Albers, Anke Baranowsky, et al.
The Journal of Cell Biology
|
February 13, 2013
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin
Joachim Albers, Johannes Keller, Anke Baranowsky, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
April 5, 2013
Impaired bone formation and increased osteoclastogenesis in mice lacking chemokine (C-C motif) ligand 5 (Ccl5)
Kristofer Wintges, F Timo Beil, Joachim Albers, et al.
Molecular Cancer Therapeutics
|
March 31, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Joachim Albers, Manja Friese-Hamim, Anderson Clark, et al.
Oncotarget
|
May 8, 2018
Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma
Laura P Brandt, Joachim Albers, Tomas Hejhal, et al.
Molecular Cancer Therapeutics
|
November 8, 2024
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation
Liana Hayrapetyan, Selina M Roth, Aurélie Quintin, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Chembiochem : a European Journal of Chemical Biology
|
January 7, 2012
A new concept for glycosyltransferase inhibitors: nonionic mimics of the nucleotide donor of the human blood group B galactosyltransferase
Katrin Schaefer, Joachim Albers, Nora Sindhuwinata, et al.
Cancers
|
January 11, 2024
DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models
Steffie Revia, Magdalena A Budzinska, Olga Bogatyrova, et al.
Plos One
|
October 6, 2017
Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma
Laura P Brandt, Joachim Albers, Tomas Hejhal, et al.
International Journal of Molecular Sciences
|
May 25, 2024
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models
Steffie Revia, Felix Neumann, Julia Jabs, et al.
Bone
|
October 3, 2009
Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism
Jochen Schulze, Joachim Albers, Anke Baranowsky, et al.
The Journal of Cell Biology
|
February 13, 2013
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin
Joachim Albers, Johannes Keller, Anke Baranowsky, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
April 5, 2013
Impaired bone formation and increased osteoclastogenesis in mice lacking chemokine (C-C motif) ligand 5 (Ccl5)
Kristofer Wintges, F Timo Beil, Joachim Albers, et al.
Molecular Cancer Therapeutics
|
March 31, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Joachim Albers, Manja Friese-Hamim, Anderson Clark, et al.
Oncotarget
|
May 8, 2018
Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma
Laura P Brandt, Joachim Albers, Tomas Hejhal, et al.
Molecular Cancer Therapeutics
|
November 8, 2024
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation
Liana Hayrapetyan, Selina M Roth, Aurélie Quintin, et al.
Page
of 3